Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasminogen activator inhibitor-1.

Ann Gils1, Paul J Declerck

  • 1Laboratory for Pharmaceutical Biology and Phytopharmacology, Katholieke Universsiteit Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium. ann.gils@pharm.kuleuven.ac.be

Current Medicinal Chemistry
|September 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

INHIBITING THE INHIBITOR: WOULD TARGETING PAI-1 RESULT IN A LOW-DOSE, WELL-TOLERATED TREATMENT OF EMPYEMA?

Biomedical sciences instrumentation·2026
Same author

Motivational factors for general practice training and career establishment: A cross-sectional study in Flanders, Belgium.

The European journal of general practice·2026
Same author

Identification of a Phage Display-Derived Peptide Interacting with the N-Terminal Region of Factor VII Activating Protease (FSAP) Enables Characterization of Zymogen Activation.

ACS chemical biology·2022
Same author

Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.

Biosensors & bioelectronics·2022
Same author

A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.

Inflammatory bowel diseases·2022
Same author

Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.

The Journal of pediatrics·2021

Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of the plasmin system, impacting cardiovascular health and tumor growth. This review covers PAI-1

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators.
  • PAI-1 is crucial in regulating fibrinolysis and has significant roles in cardiovascular diseases, cell migration, and tumor progression.
  • As a member of the serpin superfamily, PAI-1 possesses unique structural and functional characteristics.

Purpose of the Study:

  • To provide a comprehensive overview of PAI-1 knowledge accumulated over two decades.
  • To discuss the structure-function relationships of PAI-1.
  • To explore strategies for pharmacological modulation of PAI-1 as a therapeutic target.

Main Methods:

  • Literature review and synthesis of existing research on PAI-1.

Related Experiment Videos

  • Analysis of PAI-1's structural and conformational properties.
  • Examination of PAI-1's involvement in various physiological and pathological processes.

    • Main Results:

    • PAI-1's unique structural features dictate its inhibitory functions.
    • PAI-1 significantly influences cardiovascular homeostasis and tumorigenesis through t-PA and u-PA inhibition.
    • Diverse strategies exist to modulate PAI-1 activity for therapeutic benefit.

    Conclusions:

    • PAI-1 is a multifaceted protein with critical roles in health and disease.
    • Understanding PAI-1's structure-function dynamics is essential for developing targeted therapies.
    • Pharmacological targeting of PAI-1 holds promise for managing cardiovascular diseases and cancer.